KIR2DL1

KIR2DL1 Informations sur la molécule

Nom anglais	Killer cell immunoglobulin-like receptor 2DL1	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	1	Alias de la cible	KIR2DL1，NKAT-1，NKAT1，MHC class I NK cell receptor，Killer Cell Immunoglobulin Like Receptor， Two Ig Domains And Long Cytoplasmic Tail 1，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Long Cytoplasmic Tail， 1，P58 Natural Killer Cell Receptor Clones CL-42/47.11，P58 Killer Cell Inhibitory Receptor KIR-K64，Natural Killer-Associated Transcript 1，P58.1 MHC Class-I-Specific NK Receptor，CD158 Antigen-Like Family Member A，P58 NK Receptor CL-42/47.11，CD158A，Killer Cell Immunoglobulin-Like Receptor 2DL1，P58 NK Cell Inhibitory Receptor NKR-K6，Killer Inhibitory Receptor 2-2-1，KIR2DL Protein，CD158a Antigen，KIR2DL1/3DL2，KIR-K64，KIR221，P58.1，NKAT，Receptors， KIR2DL1，Cl-42
Phase de R&D la plus avancée	Phase 2 Clinical

Nom anglais	Killer cell immunoglobulin-like receptor 2DL1
Alias de la cible	KIR2DL1，NKAT-1，NKAT1，MHC class I NK cell receptor，Killer Cell Immunoglobulin Like Receptor， Two Ig Domains And Long Cytoplasmic Tail 1，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Long Cytoplasmic Tail， 1，P58 Natural Killer Cell Receptor Clones CL-42/47.11，P58 Killer Cell Inhibitory Receptor KIR-K64，Natural Killer-Associated Transcript 1，P58.1 MHC Class-I-Specific NK Receptor，CD158 Antigen-Like Family Member A，P58 NK Receptor CL-42/47.11，CD158A，Killer Cell Immunoglobulin-Like Receptor 2DL1，P58 NK Cell Inhibitory Receptor NKR-K6，Killer Inhibitory Receptor 2-2-1，KIR2DL Protein，CD158a Antigen，KIR2DL1/3DL2，KIR-K64，KIR221，P58.1，NKAT，Receptors， KIR2DL1，Cl-42
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	1
Phase de R&D la plus avancée	Phase 2 Clinical

KIR2DL1 Liste de produits

Attribut
Protein (1)
Bibliothèque de produits
En ligne (1)
Espèces
Human (1)
Étiquette
Fc Tag (1)
Marqueur
Unconjugated (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
KI1-H5255	Human	HEK293	Human KIR2DL1 / CD158a / NKAT-1 Protein, Fc Tag				Ajouter au panier

Quantité totale1

KIR2DL1Contexte de la molécule

Killer cell immunoglobulin-like receptor 2DL1(KIR2DL1), which belongs to the immunoglobulin superfamily, is an inhibitory receptor of NK cells. Regulation of NK cell activity is mediated through killer-cell immunoglobulin-like receptors (KIR) ability to recognize human leukocyte antigen (HLA) class I molecules as ligands. Interaction of KIR and HLA is implicated in viral infections, autoimmunity, and reproduction and there is growing evidence of the coevolution of these two independently segregating gene families. Association of KIR2DL1 with β-arrestin 2 mediated recruitment of the tyrosine phosphatases SHP-1 and SHP-2 to KIR2DL1 and facilitated downstream inhibitory signaling.

KIR2DL1Alias de la molécule

CD158a

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Lirilumab	IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015	Phase 2 Clinical	Novo Nordisk A/S	Bone Marrow Neoplasms; Hodgkin Disease; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Smoldering Multiple Myeloma; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms	Details